Increased gut permeability in Crohn's disease: is TNF the link?

被引：125

作者：

Gibson, PR ^{[1
]}

机构：

[1] Dept Gastroenterol, Box Hill, Vic 3128, Australia

[2] Monash Univ, Box Hill Hosp, Dept Med, Box Hill, Vic 3128, Australia

来源：

GUT | 2004年 / 53卷 / 12期

关键词：

D O I：

10.1136/gut.2004.047092

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Evidence now implicates tumour necrosis factor alpha in global impairment of intestinal barrier function, and may be the link between the leaky gut and Crohn's disease.

引用

页码：1724 / 1725

页数：2

共 24 条

[1] Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis [J].

Baert, FJ ;

D'Haens, GR ;

Peeters, M ;

Hiele, MI ;

Schaible, TF ;

Shealy, D ;

Geboes, K ;

Rutgeerts, PJ .

GASTROENTEROLOGY, 1999, 116 (01) :22-28

[2] Effect of tumor necrosis factor-α and interferon-γ on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells [J].

Belliard, AM ;

Lacour, B ;

Farinotti, R ;

Leroy, C .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (06) :1524-1536

[3]

Bojarski C, 2000, ANN NY ACAD SCI, V915, P270

[4]

Breslin NP, 2001, AM J GASTROENTEROL, V96, P2934

[5] Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms [J].

Bruewer, M ;

Luegering, A ;

Kucharzik, T ;

Parkos, CA ;

Madara, JL ;

Hopkins, AM ;

Nusrat, A .

JOURNAL OF IMMUNOLOGY, 2003, 171 (11) :6164-6172

[6] Glutamine deprivation facilitates tumour necrosis factor induced bacterial translocation in Caco-2 cells by depletion of enterocyte fuel substrate [J].

Clark, EC ;

Patel, SD ;

Chadwick, PR ;

Warhurst, G ;

Curry, A ;

Carlson, GL .

GUT, 2003, 52 (02) :224-+

[7]

CUVELIER CA, 1993, EUR J MORPHOL, V31, P87

[8] Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial [J].

D'Haens, G ;

Van Deventer, S ;

Van Hogezand, R ;

Chalmers, D ;

Kothe, C ;

Baert, F ;

Braakman, T ;

Schaible, T ;

Geboes, K ;

Rutgeerts, P .

GASTROENTEROLOGY, 1999, 116 (05) :1029-1034

[9] Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease [J].

Di Sabatino, A ;

Ciccocioppo, R ;

Cinque, B ;

Millimaggi, D ;

Morera, R ;

Ricevuti, L ;

Cifone, MG ;

Corazza, GR .

GUT, 2004, 53 (01) :70-77

[10] Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].

Hanauer, SB ;

Feagan, BG ;

Lichtenstein, GR ;

Mayer, LF ;

Schreiber, S ;

Colombel, JF ;

Rachmilewitz, D ;

Wolf, DC ;

Olson, A ;

Bao, WH ;

Rutgeerts, P .

LANCET, 2002, 359 (9317) :1541-1549

← 1 2 3 →